GlassScriptPhysician profile
Michael S Day
NPI 1376025734
$2,528.29
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,460 · 2022: $447 · 2023: $289 · 2024: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $551.84 | 2021-2023 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $453.11 | 2021-2024 | Farxiga, Lokelma |
| Coloplast Corp | $347.79 | 2021-2023 | Speedicath |
| Neurocrine Biosciences, INC. | $234.10 | 2023-2024 | Ingrezza |
| Janssen Biotech, INC. | $131.70 | 2021 | |
| Abbvie INC. | $109.17 | 2022 | |
| Scpharmaceuticals INC. | $106.00 | 2024 | |
| Esperion Therapeutics, INC. | $100.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $96.75 | 2022 | |
| Novo Nordisk INC | $91.51 | 2021 | |
| Teleflex LLC | $86.20 | 2021 | |
| Lilly USA, LLC | $79.50 | 2022 | |
| Myovant Sciences INC. | $65.02 | 2021 | |
| Endo Pharmaceuticals INC. | $37.20 | 2021 | |
| Allergan, INC. | $25.50 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.